Cencora (NYSE:COR) (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers. These services include commercialization support, market access and reimbursement consulting, patient hub and adherence programs, specialty pharmacy management, and clinical support services that help bring specialty and high-cost therapies to market and to patients efficiently.
Cencora operates across multiple geographies with a network of distribution centers, specialty pharmacies and logistics facilities that serve hospitals, health systems, retailers, independent pharmacies, physician practices and manufacturers. The company’s infrastructure and service model are geared toward handling both high-volume commodity products and complex specialty medicines, including oncology, rare disease and biologic therapies.
The company was formed through the rebranding of AmerisourceBergen in 2023 and is headquartered in Conshohocken, Pennsylvania. It is led by Steven H. Collis, who has served as chief executive officer since 2011. Cencora’s business model emphasizes integrated supply chain capabilities and services that support pharmaceutical manufacturers, payers and providers in delivering therapies to patients.
